| Title |
Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study
|
|---|---|
| Published in |
Clinical Cancer Research, December 2021
|
| DOI | 10.1158/1078-0432.ccr-21-2258 |
| Pubmed ID | |
| Authors |
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, Camille Chakiba, Alban Bessede, Michèle Kind, Emilie Toulza, Marina Pulido, Sabrina Albert, Jean-Philippe Guégan, Sophie Cousin, Simone Mathoulin-Pelissier, Raul Perret, Sabrina Croce, Jean-Yves Blay, Isabelle Ray-Coquard, Anne Floquet, Antoine Italiano |
X Demographics
The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 12% |
| Spain | 3 | 12% |
| Japan | 2 | 8% |
| United Kingdom | 2 | 8% |
| Venezuela, Bolivarian Republic of | 1 | 4% |
| France | 1 | 4% |
| Unknown | 13 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 80% |
| Practitioners (doctors, other healthcare professionals) | 3 | 12% |
| Scientists | 1 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 30% |
| Student > Ph. D. Student | 2 | 20% |
| Professor | 1 | 10% |
| Unknown | 4 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 3 | 30% |
| Medicine and Dentistry | 2 | 20% |
| Neuroscience | 1 | 10% |
| Unknown | 4 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2022.
All research outputs
#1,592,800
of 24,661,251 outputs
Outputs from Clinical Cancer Research
#1,165
of 13,075 outputs
Outputs of similar age
#39,127
of 511,980 outputs
Outputs of similar age from Clinical Cancer Research
#35
of 192 outputs
Altmetric has tracked 24,661,251 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,075 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 511,980 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.